What Is GHRP-2? Benefits, Research & Safety

GHRP-2 emerged from a research programme investigating growth hormone secretagogues in the 1980s and 1990s. The original growth hormone-releasing peptides were developed by Cyril Bowers and colleagues, who discovered that certain synthetic peptides could stimulate GH release independently of the natural GHRH pathway. GHRP-2 was identified as one of the most potent members of this peptide family. Structure-activity relationship studies helped optimise the sequence for maximal GH release. The discovery of the ghrelin receptor (GHS-R) in 1996 provided the molecular target for GHRPs. This receptor was later found to be the natural receptor for ghrelin, a gut hormone that stimulates hunger and GH release. GHRPs like GHRP-2 act as synthetic ghrelin mimetics. GHRP-2 was developed for clinical use in Japan under the name Pralmorelin, where it was approved as a diagnostic agent for GH deficiency. The peptide's potent and reliable GH-releasing effect made it useful for testing pituitary function. Research continues into GHRPs and their potential therapeutic applications beyond diagnostic use.